On-Demand | Diabetes on the Net

Diabetes on the Net is intended for healthcare professionals

Improving cardiovascular outcomes in type 2 diabetes with SGLT2 inhibitors – What is the role of the cardiologist?

The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional webcast, including speaker honoraria and presentation development support where applicable. Boehringer Ingelheim and Lilly Diabetes Alliance products will be discussed in this webcast.

Speakers

Professor Naveed Sattar

Professor of Metabolic Medicine, Institute of Cardiovascular & Medical Sciences, University of Glasgow; Honorary Consultant in Metabolic Medicine, Glasgow Royal Infirmary

Professor Martin Cowie

Professor of Cardiology, Health Services Research, Imperial College, University of London; Honorary Consultant, Royal Brompton and Harefield NHS Trust

What does this programme offer?

Join Professor Martin Cowie and Professor Naveed Sattar as they present a pre-recorded clinical discussion. Sponsored by the Boehringer Ingelheim and Lilly Diabetes Alliance.

Excess mortality in type 2 diabetes is largely related to an increased incidence of cardiovascular disease1, yet patient management has traditionally focused on improving glycaemic control – with limited evidence of macrovascular benefit.2

Since the landmark EMPA-REG OUTCOME trial in 20153 cardiovascular outcome trials have begun to provide evidence of cardiovascular benefit with some SGLT2 inhibitors and GLP-1 receptor agonists. This evidence has been reflected in new and updated guidance recommendations, including the 2019 European Society of Cardiology guidelines on diabetes, pre-diabetes and cardiovascular disease4 – in light of this, do cardiologists have an expanded role in treating type 2 diabetes?

The presentations cover topics including:

Putting the evidence into practice: does the cardiologist have an expanded role in the treatment of type 2 diabetes?

Professor Martin Cowie​

For adverse events reporting and prescribing information UKIE

Type 2 diabetes, cardiovascular outcomes and the role of SGLT2 inhibitors

Professor Naveed Sattar

For adverse events reporting and prescribing information UKIE

Jardiance is the most initiated SGLT2i inhibitor in the UK5*

Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise6

Both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.6

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 3281627 (freephone)

Adverse events should be reported. Reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue 
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 2913960 Fax: +44 1344 742661
or by email: PV_local_UK_Ireland@boehringer-ingelheim.com
*

Defined as new patients prescribed JARDIANCE, patients switched to JARDIANCE from another type 2 diabetes treatment or JARDIANCE added to another type 2 diabetes treatment

References
1. Tancredi M et al. N Engl J Med. 2015;373:1720–1732.
2. Turnbull FM et al. Diabetologia. 2009;52:2288–2298.3. Zinman B et al. N Engl J Med. 2015;373:2117–2128.
4. Cosentino F et al. Eur Heart J 2020;41:255.
5. Data on file. IQVIA new patient opportunity data June 2020. Boehringer Ingelheim.
6. Jardiance Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/28973 (accessed October 2020)

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.